دورية أكاديمية
Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
| العنوان: | Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. |
|---|---|
| المؤلفون: | Cocks M; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Chaux A; Department of Scientific Research, School of Postgraduate Studies, Norte University, Asunción, Paraguay., Jenson EG; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Miller JA; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Rodriguez Pena MDC; Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA., Tregnago AC; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Taheri D; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.; Isfahan Kidney Diseases Research Center, Pathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran., Eich ML; Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA.; Department of Pathology, University Hospital Cologne, Cologne, Germany., Sharma R; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Vang R; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA., Netto GJ; Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA. gnetto@uabmc.edu. |
| المصدر: | Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Jul; Vol. 477 (1), pp. 93-102. Date of Electronic Publication: 2020 Jan 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York : Springer International, c1994- |
| مواضيع طبية MeSH: | Carcinoma, Squamous Cell/*pathology , Neoplasm Recurrence, Local/*pathology , Tumor Microenvironment/*immunology , Vulvar Neoplasms/*pathology, Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor/analysis ; Carcinoma, Squamous Cell/immunology ; Female ; Humans ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/pathology ; Middle Aged ; Neoplasm Recurrence, Local/immunology ; Vulvar Neoplasms/immunology |
| مستخلص: | Vulvar squamous cell carcinoma accounts for 5% of cancers of the female genital tract. Current guidelines recommend wide local excision with negative surgical margins as the standard treatment. However, the extent of the tumor-free resection margin after wide local excision is still controversial in many cases. Drugs targeting immune checkpoints such as PD-1 or its ligand PD-L1 have potential clinical utility in these patients. We examined the expression of PD-L1 in tumor cells and immune cells, as well as the proportion of PD-1, CD8, and FOXP3 positive lymphocytes. Twenty-one cases of invasive vulvar squamous cell carcinomas were reviewed. Whole slides of representative formalin-fixed, paraffin-embedded archival material were used for analysis. Odds ratios (OR) and hazard ratios (HR) were used to estimate risk for disease recurrence, overall mortality, and cancer mortality. PD-L1 expression was found in 43% of tumor cells, with higher proportions in intratumoral (67%) and peritumoral (81%) immune cells. OR and HR for disease recurrence and cancer mortality were higher in tumors with higher CD8 expression. OR and HR for overall mortality were also higher in tumors with higher PD-L1 and CD8 expression. In conclusion, nearly half of cases were PD-L1 positive in tumor cells with over two-third of cases demonstrating PD-L1 positivity in immune cells. Immunohistochemical expression of PD-L1 and CD8 could be used to suggest higher risk of disease recurrence, overall mortality, and cancer mortality. Furthermore, our data contributes to the growing evidence that targeting the PD-1/PD-L1 pathway may be beneficial in vulvar squamous cell carcinomas. |
| فهرسة مساهمة: | Keywords: Checkpoint inhibitor; Immunotherapy; Outcome; PD-1; PD-L1; Prognosis; Squamous cell carcinoma; Tumor microenvironment; Vulva |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 0 (Biomarkers, Tumor) 0 (CD274 protein, human) |
| تواريخ الأحداث: | Date Created: 20200130 Date Completed: 20200709 Latest Revision: 20240627 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1007/s00428-020-02759-y |
| PMID: | 31993774 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-2307 |
|---|---|
| DOI: | 10.1007/s00428-020-02759-y |